Cargando…

Can analyses of electronic patient records be independently and externally validated? Study 2—the effect of β-adrenoceptor blocker therapy on cancer survival: a retrospective cohort study

OBJECTIVES: To conduct a fully independent, external validation of a research study based on one electronic health record database using a different database sampling from the same population. DESIGN: Retrospective cohort analysis of β-blocker therapy and all-cause mortality in patients with cancer....

Descripción completa

Detalles Bibliográficos
Autores principales: Springate, David A, Ashcroft, Darren M, Kontopantelis, Evangelos, Doran, Tim, Ryan, Ronan, Reeves, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4401857/
https://www.ncbi.nlm.nih.gov/pubmed/25869690
http://dx.doi.org/10.1136/bmjopen-2014-007299
_version_ 1782367205579554816
author Springate, David A
Ashcroft, Darren M
Kontopantelis, Evangelos
Doran, Tim
Ryan, Ronan
Reeves, David
author_facet Springate, David A
Ashcroft, Darren M
Kontopantelis, Evangelos
Doran, Tim
Ryan, Ronan
Reeves, David
author_sort Springate, David A
collection PubMed
description OBJECTIVES: To conduct a fully independent, external validation of a research study based on one electronic health record database using a different database sampling from the same population. DESIGN: Retrospective cohort analysis of β-blocker therapy and all-cause mortality in patients with cancer. SETTING: Two UK national primary care databases (PCDs): the Clinical Practice Research Datalink (CPRD) and Doctors’ Independent Network (DIN). PARTICIPANTS: CPRD data for 11 302 patients with cancer compared with published results from DIN for 3462 patients; study period January 1997 to December 2006. PRIMARY AND SECONDARY OUTCOME MEASURES: All-cause mortality: overall; by treatment subgroup (β-blockers only, β-blockers plus other blood pressure lowering medicines (BPLM), other BPLMs only); and by cancer site. RESULTS: Using CPRD, β-blocker use was not associated with mortality (HR=1.03, 95% CI 0.93 to 1.14, vs patients prescribed other BPLMs only), but DIN β-blocker users had significantly higher mortality (HR=1.18, 95% CI 1.04 to 1.33). However, these HRs were not statistically different (p=0.063), but did differ for patients on β-blockers alone (CPRD=0.94, 95% CI 0.82 to 1.07; DIN=1.37, 95% CI 1.16 to 1.61; p<0.001). Results for individual cancer sites differed by study, but only significantly for prostate and pancreas cancers. Results were robust under sensitivity analyses, but we could not be certain that mortality was identically defined in both databases. CONCLUSIONS: We found a complex pattern of similarities and differences between databases. Overall treatment effect estimates were not statistically different, adding to a growing body of evidence that different UK PCDs produce comparable effect estimates. However, individually the two studies lead to different conclusions regarding the safety of β-blockers and some subgroup effects differed significantly. Single studies using even internally well-validated databases do not guarantee generalisable results, especially for subgroups, and confirmatory studies using at least one other independent data source are strongly recommended.
format Online
Article
Text
id pubmed-4401857
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-44018572015-04-29 Can analyses of electronic patient records be independently and externally validated? Study 2—the effect of β-adrenoceptor blocker therapy on cancer survival: a retrospective cohort study Springate, David A Ashcroft, Darren M Kontopantelis, Evangelos Doran, Tim Ryan, Ronan Reeves, David BMJ Open General practice / Family practice OBJECTIVES: To conduct a fully independent, external validation of a research study based on one electronic health record database using a different database sampling from the same population. DESIGN: Retrospective cohort analysis of β-blocker therapy and all-cause mortality in patients with cancer. SETTING: Two UK national primary care databases (PCDs): the Clinical Practice Research Datalink (CPRD) and Doctors’ Independent Network (DIN). PARTICIPANTS: CPRD data for 11 302 patients with cancer compared with published results from DIN for 3462 patients; study period January 1997 to December 2006. PRIMARY AND SECONDARY OUTCOME MEASURES: All-cause mortality: overall; by treatment subgroup (β-blockers only, β-blockers plus other blood pressure lowering medicines (BPLM), other BPLMs only); and by cancer site. RESULTS: Using CPRD, β-blocker use was not associated with mortality (HR=1.03, 95% CI 0.93 to 1.14, vs patients prescribed other BPLMs only), but DIN β-blocker users had significantly higher mortality (HR=1.18, 95% CI 1.04 to 1.33). However, these HRs were not statistically different (p=0.063), but did differ for patients on β-blockers alone (CPRD=0.94, 95% CI 0.82 to 1.07; DIN=1.37, 95% CI 1.16 to 1.61; p<0.001). Results for individual cancer sites differed by study, but only significantly for prostate and pancreas cancers. Results were robust under sensitivity analyses, but we could not be certain that mortality was identically defined in both databases. CONCLUSIONS: We found a complex pattern of similarities and differences between databases. Overall treatment effect estimates were not statistically different, adding to a growing body of evidence that different UK PCDs produce comparable effect estimates. However, individually the two studies lead to different conclusions regarding the safety of β-blockers and some subgroup effects differed significantly. Single studies using even internally well-validated databases do not guarantee generalisable results, especially for subgroups, and confirmatory studies using at least one other independent data source are strongly recommended. BMJ Publishing Group 2015-04-13 /pmc/articles/PMC4401857/ /pubmed/25869690 http://dx.doi.org/10.1136/bmjopen-2014-007299 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/
spellingShingle General practice / Family practice
Springate, David A
Ashcroft, Darren M
Kontopantelis, Evangelos
Doran, Tim
Ryan, Ronan
Reeves, David
Can analyses of electronic patient records be independently and externally validated? Study 2—the effect of β-adrenoceptor blocker therapy on cancer survival: a retrospective cohort study
title Can analyses of electronic patient records be independently and externally validated? Study 2—the effect of β-adrenoceptor blocker therapy on cancer survival: a retrospective cohort study
title_full Can analyses of electronic patient records be independently and externally validated? Study 2—the effect of β-adrenoceptor blocker therapy on cancer survival: a retrospective cohort study
title_fullStr Can analyses of electronic patient records be independently and externally validated? Study 2—the effect of β-adrenoceptor blocker therapy on cancer survival: a retrospective cohort study
title_full_unstemmed Can analyses of electronic patient records be independently and externally validated? Study 2—the effect of β-adrenoceptor blocker therapy on cancer survival: a retrospective cohort study
title_short Can analyses of electronic patient records be independently and externally validated? Study 2—the effect of β-adrenoceptor blocker therapy on cancer survival: a retrospective cohort study
title_sort can analyses of electronic patient records be independently and externally validated? study 2—the effect of β-adrenoceptor blocker therapy on cancer survival: a retrospective cohort study
topic General practice / Family practice
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4401857/
https://www.ncbi.nlm.nih.gov/pubmed/25869690
http://dx.doi.org/10.1136/bmjopen-2014-007299
work_keys_str_mv AT springatedavida cananalysesofelectronicpatientrecordsbeindependentlyandexternallyvalidatedstudy2theeffectofbadrenoceptorblockertherapyoncancersurvivalaretrospectivecohortstudy
AT ashcroftdarrenm cananalysesofelectronicpatientrecordsbeindependentlyandexternallyvalidatedstudy2theeffectofbadrenoceptorblockertherapyoncancersurvivalaretrospectivecohortstudy
AT kontopantelisevangelos cananalysesofelectronicpatientrecordsbeindependentlyandexternallyvalidatedstudy2theeffectofbadrenoceptorblockertherapyoncancersurvivalaretrospectivecohortstudy
AT dorantim cananalysesofelectronicpatientrecordsbeindependentlyandexternallyvalidatedstudy2theeffectofbadrenoceptorblockertherapyoncancersurvivalaretrospectivecohortstudy
AT ryanronan cananalysesofelectronicpatientrecordsbeindependentlyandexternallyvalidatedstudy2theeffectofbadrenoceptorblockertherapyoncancersurvivalaretrospectivecohortstudy
AT reevesdavid cananalysesofelectronicpatientrecordsbeindependentlyandexternallyvalidatedstudy2theeffectofbadrenoceptorblockertherapyoncancersurvivalaretrospectivecohortstudy